1. Clinical Overview
Molecule: Mazdutide (IBI362) — novel once-weekly synthetic dual-receptor peptide agonist of GLP-1R and GCGR.
Classification: GLP-1/glucagon dual agonist • Investigational anti-obesity therapeutic • Emerging alternative to tirzepatide and survodutide
Simultaneously suppresses appetite/food intake, stimulates energy expenditure via glucagon pathway, enhances glycemic control, lipid metabolism, and visceral fat reduction.
2. Mechanisms of Action
2.1 GLP-1R Agonism
Glucose-dependent insulin secretion, glucagon secretion inhibition, delayed gastric emptying, satiety promotion, appetite reduction.
2.2 GCGR Agonism
Hepatic lipid oxidation, thermogenesis and energy expenditure, fat store mobilization.
2.3 Dual-Synergistic Activity
GLP-1 mediates caloric reduction while glucagon drives fat loss and energy burn. May offer superior body composition preservation vs GLP-1 monotherapy.
3. Evidence Summary — Clinical Trials
3.1 Phase 1 & 2 Highlights
Up to 15.4% total body weight loss over 20–32 weeks (comparable to tirzepatide). Substantial reduction in visceral adipose tissue and waist circumference. Improvements in fasting glucose, insulin, HbA1c, and HOMA-IR.
3.2 Body Composition
Favorable lean mass retention. Enhanced fat oxidation (respiratory quotient).
3.3 Lipid & Inflammatory Markers
Reduced triglycerides and LDL. Modest improvements in CRP and adiponectin.
3.4 NAFLD/NASH Implications
MRI-PDFF data shows reduced liver fat fraction. Anti-steatotic effect supports hepatic protocol exploration.
4. Clinical Protocols
Titrate gradually to minimize GI effects — avoid escalation with unresolved nausea/vomiting
Dose Titration Schedule
| Week | Dose (mg/week) |
|---|---|
| 1–4 | 1.5 mg |
| 5–8 | 3.0 mg |
| 9–12 | 4.5 mg |
| 13+ | 6.0 mg maintenance (max: 9.0 mg) |
5. Clinical Integration Strategies
+ 5-Amino-1MQ or MOTS-c: Visceral adiposity + mitochondrial optimization
+ SLU-PP-332: Enhanced thermogenesis, UCP-1 activation
+ REVIVE™ AM or NAD+ Stack: Liver fat reduction + glucose/insulin sensitivity
6. Clinical Archetypes
Archetype A — Obesity / Body Recomposition
Mazdutide 6.0 mg weekly + CJC/Ipamorelin + Resistance training emphasis
Archetype B — Metabolic Syndrome / Prediabetes
Mazdutide 3.0–4.5 mg + MOTS-c (3×/week) + Berberine, omega-3s
Archetype C — NASH/NAFLD Candidate
Mazdutide + SLU-PP-332 or SS-31 + REVIVE™ mitochondrial stack
7. Decision Tree for Clinical Use
| Scenario | Mazdutide Role |
|---|---|
| Obesity with insulin resistance | Strong candidate |
| Visceral adiposity & metabolic inflexibility | Ideal candidate |
| History of GLP-1 intolerance | Use with caution |
| Desire for lean mass preservation | Consider CJC-1295 co-therapy |
| Previous pancreatitis | Contraindicated |
8. Safety, Side Effects & Monitoring
Common Side Effects
Nausea, vomiting, constipation, appetite suppression, fatigue.
Contraindications
- Pregnancy and breastfeeding
- Personal/family history of medullary thyroid cancer or MEN2
- History of pancreatitis
Monitoring
- Baseline and periodic CMP
- HbA1c, insulin, fasting glucose q12 weeks
- Weight, waist circumference, liver function tests
Legal Disclaimer
This document is provided solely for educational and informational purposes. Mazdutide and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.
References — Mazdutide Clinical Reference Guide
Provider Access Required
Create a provider account to read the full clinical guide for Mazdutide (IBI362).